CG Oncology Inc. (CGON) vs Erasca, Inc. (ERAS)
A side-by-side comparison of CG Oncology Inc. and Erasca, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CGON
CG Oncology Inc.
$68.71HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
ERAS
Erasca, Inc.
$14.72HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — CGON vs ERAS
growth of $100 · dividends reinvested · last 3yCGON +84.9% (+22.7%/yr)ERAS +771.0% (+105.8%/yr)ERAS compounded faster over this window
CGON ERAS
CGON vs ERAS: by the numbers
- •CGON is the larger company ($6.06B vs $5.11B market cap).
- •Both run net losses; ERAS's is the smaller (0.00% vs -3602.68% net margin).
Metrics side by side
Valuation
| Metric | CGON | ERAS |
|---|---|---|
| P/S ratio | 973.09 | N/A |
| P/B ratio | 5.89 | 14.12 |
Profitability
| Metric | CGON | ERAS |
|---|---|---|
| Gross margin | -15.02% | 0.00% |
| Operating margin | -4722.13% | 0.00% |
| Net margin | -3602.68% | 0.00% |
| ROE | -21.80% | -79.37% |
| ROIC | -24.33% | -38.03% |
Growth (annualized)
| Metric | CGON | ERAS |
|---|---|---|
| Total return CAGR (5Y) | N/A | -8.34% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.